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incidence of PVE, which is most often due to hospital acquired
pathogens
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Risk factors associated with persistence of
staphylococcus aureus bacteremia
T. Kitazawa ∗, K. Seo, I. Koga, Y. Ota
Teikyo University, Tokyo, Japan
Background: Staphylococcus aureus bacteremia (SAB) is one
of the serious nosocomial or community acquired infections. SAB
can persist longer as compared to bacteremia with other bacteria,
althoughwhether risk factors associatedwith persistent SABwhich
pointed out in previous studies are related to its persistency of SAB
in the settings with different antibiotic resistant rate and different
antibiotic use. In this study, we determined clinical characteristics
and risk factors for persistent SAB by comparing persistent SAB
cases and non-persistent SAB cases in Japan.
Methods & Materials: All the ﬁrst episodes of adult SAB cases
in 1,150 bed academic medical hospital in Japan form May 2009
through April 2014 were enrolled. The onset of SAB was deﬁned
as the time when the ﬁrst positive blood cultures were collected.
Persistent SABwas deﬁned as a case inwhich positive blood culture
persisted 72 hours or longer, and non-persistent SAB was deﬁned
as a case negativity of blood culture was veriﬁed within 72 hours.
Clinical backgrounds, primary infection sites, methicillin resistant
or not (MRSA or MSSA), vancomycin susceptibility, and antibiotic
use were retrospectively reviewed from medical records.
Results: Of 618 SAB cases, MRSA cases and MSSA cases were
293 and 325 cases, respectively. Persistent SAB were 42 cases,
non-persistent SAB were 34 cases. Median persistent periods of
persistent SAB and non-persistent SAB were 2 days and 8 days,
respectively. Clinical backgrounds and primary infection sites pri-
mary infection sites were similar between the two groups. The rate
of MRSA was in persistent SAB was statistically higher than that
of non-persistent SAB (93% vs 35%, P<0.001)(Fig. 1). Although sus-
ceptibilities to vancomycin, were similar between the two groups,
the timing of susceptible antibiotics use in persistent SAB was later
than that in non-persistent SAB (2 days vs 0 days, P <0.001) (Fig. 2).
Fig. 1. Methicillin susceptibility of SA and SAB persistence.
Fig. 2. Delay of antibiotic use and SAB persistence.
Conclusion: In our study, persistence of SAB were associated
with MRSA as a pathogen, delay in susceptible antibiotic use, but
notwith clinical backgroundsnorwithvancomycin susceptibilities.
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Background: The rising incidence and worsening severity of
Clostridium difﬁcile infection (CDI) have prompted improvements
in the treatment of CDI in many countries. Vancomycin (VCM) and
Metronidazole (MNZ) are both widely used. VCM may bring about
a better clinical response and outcome than MNZ in treating CDI,
especially severe CDI. The optimal treatment for CDI, however, has
yet tobeestablished in Japan.Dosages anddurationsofmedications
for CDI have not been clearly described in previous studies, and
MNZ has only recently been approved for CDI under the national
health insurance system. Our group conducted Japan’s ﬁrst multi-
center retrospective study to investigate the optimal treatment
for CDI by comparing outcomes between MNZ- and VCM-treated
groups at variable dosages and treatment durations.
Methods & Materials: CDI patients hospitalized at four teach-
ing hospitals from April 2012 through September 2013 were
enrolled. CDIwasdiagnosedwhenCD toxinwaspositivebyenzyme
immunoassay test in stool. Thepatientswere treated for 10-14days
with oral MNZ (1000 or 1500 mg per day: MNZ group) or oral VCM
(500 mg per day: VCM group). Kaplan-Meier curves were created
to compare the survival curves between MNZ- and VCM-treated
patients.
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Results: We tested 3,921 stool samples and identiﬁed 170
patients with CDI (1.04 cases per 10,000 patient-days). Seventy-
eight of the CDI patients were treated with MNZ and 41 were
treated with VCM. No signiﬁcant demographic or clinical differ-
ences were found between the two groups. The 90-day all-cause
mortality rates in the MNZ and VCM groups were 16.2% and
28.9%, respectively. The survival curves did not differ signif-
icantly between the two groups after adjusting for several
confounders established to be independent risk factors for severe
or complicated-course CDI (age, hypoalbuminemia, acute kidney
injuries, leukocytosis, hypotension or shock).
Conclusion: Our study, Japan’s ﬁrst multi-center assessment
of CDI treatment, showed no signiﬁcant difference in prognosis
between theMNZgroupandVCMgroup.WeexpectMNZtobecome
a drug of choice for the treatment of CDI.
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Clinical proﬁle, susceptibility patterns,
treatment and outcomes of melioidosis in India
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2 Christian Medical college, Vellore, India
Background: Melioidosis, caused by Burkholderia pseudomallei,
is endemic to India and has been associated with signiﬁcant mor-
bidity and mortality. Since it mimics several other diseases, it is
grossly under-recognised. This study was undertaken to describe
the clinical manifestations, drugsusceptibility and outcomes of
melioidosis in India.
Methods & Materials: We carried out a retrospective study of
adultpatients admittedwithcultureprovenmelioidosis ina tertiary
care hospital in South India from 2008 to 2014.
Results: 114 patients, with a mean age of 45 years (92%
males) were included. The patients were from 15 states, major-
ity being from West Bengal (26.3%), Jharkhand (22.8%) and Tamil
Nadu (14.9%). Common risk factors included diabetes (82.3%),
and alcoholism (14%). The mean duration of symptoms, com-
monly fever, was 4 months and majority (78%) had multifocal
disease. Patients presented in the cooler months (80.5%), espe-
cially in the acute group. Chronic melioidosis was commoner
than acute disease (64% vs 36%). 11 patients (15%) among chronic
melioidosis presented with an acute worsening and bacteremia.
Bacteremia (80% vs 41%) and respiratory involvement (39% vs
16%) were more common in acute disease. Chronic granulomatous
disease was associated with splenic (50% vs 29%), genitourinary
(17.8 vs 4.9%) and bone involvement (12.3 vs 7%). Drug sus-
ceptibility to Carbepenems was 100%, Ceftazidime 98.1% while
resistance to Trimethoprim-Sulfamethoxazole and Doxycycline
was 5.9% and 2.6%. Our patients received induction therapy with
CeftazidimeorMeropenemfollowedbyeradication treatmentwith
Trimethoprim-Sulfamethoxazole and Doxycycline. 50.9% patients
required a surgical intervention and 21.9% were admitted to an
intensive care unit. The case fatality rate was 14.9%. Bacteremia
(p <0.001) and respiratory involvement (p=0.003) were associated
with increasedmortality. 57.9% patientswere followed up and 3.5%
patients had a relapse.
Conclusion: Melioidosis is an emerging infection in India.
Majority of the patients are diabetics presenting with chronic
granulomatous disease. Patients with septicemia and respiratory
involvement had poorer outcome. A high index of suspicion in
the appropriate clinical setting, and early initiation of therapy are
essential.
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Emerging trends in the antibiotic susceptibility
pattern of vibrio cholerae in North Karnataka
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Background: Acute diarrhoea is the second most prevalent
communicable disease and a fourth leading cause of death in India
with 10762500 cases and 32218 deaths reported in 2013. Cholera
is an acute diarrhoeal illness caused by toxigenic strains of Vibrio
cholerae serogroups O1 and O139. This study has been done with
the aim of evaluating the serogroups, antimicrobial susceptibility
pattern, age andgenderwise distributionofVibrio cholerae isolates
from cholera epidemics in Bidar and rural parts of north Karnataka,
India during the years 2008 to 2015 till date.
Methods & Materials: A total 500 stool samples of cholera out-
break fromYear 2008 to 2015 till datewere collected andprocessed
at Department of Microbiology, Bidar Institute of Medical Sciences,
Bidar, Karnataka, India as per the routinemicrobiological investiga-
tions. The isolateswere identiﬁed as Vibrio cholerae and conﬁrmed
by serological tests with Polyvalent O1, O139 and mono speciﬁc
Ogawa and Inaba antisera. Antibiotic sensitivity testing was done
as per the CLSI guidelines.
Results: Vibrio cholerae biotype ElTor, sero group O1 grown in
155 samples (31%). Among 155 isolates obtained, of which, 136
(87.74%) were belonged to Ogawa, 13 (8.3%) belonged to Inaba
and 06 (03.8%) to Hikozima. The isolates showed Multi drug resis-
tance to Ampicillin (81.93%), Nalidixic acid (66.45%) and Oﬂoxacin
(32.90%) throughout the study period. And Vibrio cholerae isolates
showed resistance to Ciproﬂoxacin (22.58%), Doxycycline (14.83%)
and Tetracycline (16.77%) indicating development of resistance
of V. Cholerae to the drugs which are commonly used to treat
Cholera infection. The infection was predominant in male and
among patients age between 0-10 years (26%).
Conclusion: This is the ﬁrst study conducted in the North Kar-
nataka which reﬂects the importance of control and monitoring
of V. cholerae by serogroup and antibiogram typing for policy
makers and health professionals of this region as incidence of
cholera increased year wise and changing trend in the antibiotic
susceptibility pattern of V. cholerae was observed which is due to
environmental factors and widespread use of antibiotics.
